International Journal of Endocrinology and Metabolism

Published by: Kowsar

Raloxifene in Hemodialysis Patients

Frieder Keller 1 , *
Author Information
1 Nephrology Department, University Hospital, Ulm, Germany
Article information
  • International Journal of Endocrinology and Metabolism: June 01, 2012, 10 (3); 576-576
  • Published Online: June 30, 2012
  • Article Type: Letter
  • Received: May 6, 2012
  • Revised: May 7, 2012
  • Accepted: May 7, 2012
  • DOI: 10.5812/ijem.5457

To Cite: Keller F. Raloxifene in Hemodialysis Patients, Int J Endocrinol Metab. 2012 ;10(3):576-576. doi: 10.5812/ijem.5457.

Copyright © 2012, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando S, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab. 2012; 10: 464-9[DOI]
  • 2. Czock D, Keller F, Heringa M, Rasche FM. Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol. 2005; 59(4): 479-82[DOI][PubMed]
  • 3. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008; 19(7): 1430-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments